抗微生物药物耐药性监测与行动的未来的反思
本文基于弗莱明基金近十年的经验,通过参与式综合方法,总结了中低收入国家抗微生物药物耐药性(AMR)监测的经验教训与未来考量。文章指出AMR监测投资已取得显著进展,但未来需要扩大国内公共融资、私营部门参与或多边支持以维持成果,并需设计良好、有针对性且成本有效的投资来加强系统。
要点
- AMR监测需在资源约束下规划,聚焦数据范围、频率和深度以支持行动。
- 未来需扩大国内公共融资、私营部门参与或多边支持以维持进展。
- 进展需要设计良好、有针对性且成本有效的投资来维持能力并加强系统。
核心结论
- AMR监测和更广泛AMR行动的投資已取得实质性进展。
- 需扩大国内公共融资、大规模私营部门参与或增强多边支持以确保持续成果。
- 进展需要设计良好、有针对性和成本有效的投资,以维持当前能力并进一步加强系统。
研究设计与样本
- 参与式综合方法,涉及与曾在弗莱明基金内及 alongside 工作的个人合作,来自14个组织的贡献者组成写作组。
- 综合基于4次虚拟研讨会的贡献和3份手稿草案。
主要发现
- 近10年来,弗莱明基金在AMR监测方面取得了显著改善。
- 对跨环境和系统的障碍与促进因素的分析突出了监测定位、资助、使用和创新方面的关键教训。
- 未来AMR监测的成功和可持续性依赖于在资源约束下规划一个更精准的系统,聚焦数据的范围、频率和深度以支持行动。
临床怎么用
- 在资源约束下规划AMR监测系统,聚焦数据范围、频率和深度以支持行动。
- 通过技术支持、架构发展方向来简化投资和融资,支持国家主导的可持续方法。
- 考虑扩大国内公共融资、私营部门参与或多边支持以维持监测能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This paper builds on the other papers in this series to present high-level lessons learnt and considerations for the future of antimicrobial resistance (AMR) surveillance and its contribution to action on AMR in low- and middle-income countries. METHODS: Participatory synthesis involved engagement with individuals who had worked within and alongside the Fleming Fund from a range of organizations and geographies, to scope and solidify lessons learnt and future considerations relevant to a wide range of donors, partners, and policy makers or implementors. Contributors were invited to join a Writing Group, which included individuals from academia, clinical sciences, applied public, animal, environment, and food sciences health, as well as senior scientists and administrators from 14 organizations. The synthesis was informed by contributions to 4 virtual workshops and 3 drafts of the manuscript. Authors read and commented on the drafts, several wrote and referenced sections, and all gave substantive feedback with their reactions to the draft conclusions as consensus was built. RESULTS: Over nearly 10 years, the Fleming Fund achieved significant improvements in AMR surveillance. Analysis of the barriers and enablers across settings and systems highlights key lessons for how surveillance is positioned, funded, used, and innovated upon. The success of future AMR surveillance and its sustainability relies on planning within resource constraints for a sharpened system that focuses the scope, frequency, and depth of data to inform action, technical, and architectural developments directions to streamline investment and financing that supports country-led sustainable approaches. CONCLUSIONS: Investment in AMR surveillance and broader AMR actions has yielded substantial progress. Expanded domestic public financing, large-scale private sector engagement, or enhanced multilateral support will be needed to ensure recent gains are sustained. Progress will require well-designed, targeted, and cost-effective investments to maintain current capacity while enabling further system strengthening.
引用
- Chandler CIR, Abbas S, Amir A, et al. Reflections for the Future of AMR Surveillance and AMR Action. Clin Infect Dis. 2026. PMID: 42895840. doi:10.1093/cid/ciag498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。